Global pharma major Lupin Limited (Lupin) will present data from its Phase 1a clinical trial evaluating LNP7457, a PRMT5 inhibitor, at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, Illinois, from May 30 to June 3, 2025.

• The presentation, titled "A phase 1 dose escalation study of LNP7457 (PRMT5 inhibitor) in patients with advanced or metastatic solid tumors," will be featured in the Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology session.
• It can be viewed at Poster Board #422 on June 2, 2025, from 1:30 pm to 4:30 pm (CDT).
• Key findings from the study indicate that LNP7457 is generally safe and well tolerated in patients with advanced or metastatic solid tumors, exhibiting a desirable PK/PD profile with no impact of food on pharmacokinetics.
• The maximum tolerated dose and recommended phase 2 dose were determined based on safety, efficacy, and PK/PD data, aligning with preclinical findings and the known safety profile of PRMT5 inhibitors.
• Vinita Gupta, CEO, expressed delight in sharing the initial results from the Phase I study of their PRMT5 Inhibitor, a novel epigenetic onco-therapeutic targeted for monotherapy. She emphasized Lupin's commitment to innovation and advancing cutting-edge science to offer meaningful therapeutic options for patients with difficult-to-treat cancers.
• Lupin will continue to study the efficacy of LNP7457 in its phase 1b trial in India and explore its potential for treatment of cancers with significant unmet medical needs.